Beneficial Effect of Luteal-phase Gonadotropin-releasing Hormone Agonist Administration on Implantation Rate Afterintracytoplasmic Sperm Injection

Abstract

Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome. Materials and Methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes. Results: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo. Conclusion: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.

Keywords

• embryo implantation
• GnRH agonist
• intracytoplasmic sperm injection
• luteal phase support